Patheon Inc

Patheon — Q2 2006 Earnings Presentation

10 slides from Patheon's earnings presentation, Jun 2, 2006

  1. Slide 1: Q2 2006 Financial Results Conference Call

    Q2 2006 FINANCIAL RESULTS CONFERENCE CALL June 2, 2006 10:00 a.m. (EDT) STRATEGIC RELATIONSHIPS | TECHNOLOGIES | PRODUCTS Presenting on behalf of Patheon • PETER GREEN Chairman of the Board of Directors and Office of the Chief Executive Officer • NICK DIPIETRO President and Chief Operating Officer a

  2. Slide 2: Agenda; Forward-looking Information

    Agenda • Overview of Q2 and YTD results (S. Jourard) • Current issues (D. Ludwig) – Q2 performance drivers – Outlook • Business Review (N. DiPietro) – Update on Puerto Rico – Revenue development • Concluding remarks (P. Green) – Performance Enhancement Program – Update on CEO search • Q&A Forward-lo

  3. Slide 3: Q2 2006 Highlights and 1st Half 2006 Highlights

    Q2 2006 Highlights • Revenues up 3% to $189.9M • EBITDA of $24.2M (12.8% of revenues) vs. $24.3M (13.2% of revenues) a year ago • Net earnings of $3.0M vs. $3.8M a year ago • EPS of 3.2¢/share vs. 3.4¢/share a year ago 1st Half 2006 Highlights • Revenues up 3% to $347.8M • EBITDA of $38.2M (11.0% of

  4. Slide 4: Current Issues: Performance Highlights

    CURRENT ISSUES Performance Highlights ƒ Revenues up 20% over Q1 and 3% YOY ƒ EBITDA up $10.2M (73%) over Q1, but flat YOY ƒ Impact of currency fluctuations – Further strengthening of Canadian dollar relative to U.S. dollar decreased reported EBITDA of Canadian operations by ~$1.6M YOY ƒ Effective ta

  5. Slide 5: Earnings Performance: Challenges and Achievements

    Earnings performance: Challenges ƒ Puerto Rico commercial manufacturing EBITDA declined by ~55% to $4.4M – Reduced revenues and profitability on a large-volume generic product – Added costs to address FDA Warning Letter issues ƒ Global PDS EBITDA declined by 31% to $3.4M – Good growth at Cincinnati

  6. Slide 6: Outlook for balance of 2006

    Outlook for balance of 2006 ƒ Continued improvements in commercial manufacturing revenues in Canada and Europe ƒ Lower commercial manufacturing revenues in U.S. relative to 2005 ƒ Accelerated PDS revenue growth, driven by Cincinnati and Swindon ƒ Second half 2006 revenues expected to be slightly hig

  7. Slide 7: Update on Puerto Rico; Major New Business: Swindon, U.K.

    Update on Puerto Rico • FDA re-inspection of Carolina facility – Inspection underway – Awaiting report • Cedfinir ANDA (Omnicef® capsules, 300 mg) – Capsules represent less than 10% of PTI revenues from Omnicef® – Abbott’s compound patent protection extends until May 2007; the company has a formulat

  8. Slide 8: Major New Business: Manati, Puerto Rico

    Major New Business: Manati, Puerto Rico Manati, Puerto Rico 1. Global Pharma Client ƒ Two products ƒ Tech transfer agreement for first product signed ƒ Long-term agreements under negotiation ƒ Commercial Rx volumes in 2007 Major New Business: Manati, Puerto Rico Manati, Puerto Rico 1. Global Pharma

  9. Slide 9: Conclusion: Performance Enhancement Program

    CONCLUSION Performance Enhancement Program ƒ Patheon is well established as the market leader in pharmaceutical outsourcing, but we need to improve profitability and cash generation ƒ We have initiated a performance enhancement program ƒ Program to include quantifiable objectives and timetables that

  10. Slide 10: CEO Succession

    CEO Succession ƒ Board Succession Committee actively engaged in the search for the new CEO ƒ Expect to complete the process during the fourth quarter ƒ Work on the performance enhancement program will proceed while the CEO search is underway ƒ Committed to swift and decisive action that will improve

Patheon — Q2 2006 Earnings Presentation on 6ix